- 회사소개
- 연구개발
- 사업분야
- IR / PR
- 공지사항
R & D
DIABETIC RETINOPATHY
Diabetic Retinopathy Overview
- Diabetic Retinopathy (DR) is caused by ischemia due to damage to retinal microvasculature, and is a major complication of diabetes (25% of diabetic patients)
- Diabetic patients are rapidly increasing due to the aging population and change in lifestyle habits
Diabetic Retinopathy Stages
(Source: A proposal for early and personalized treatment of diabetic retinopathy based on
clinical pathophysiology and molecular phenotyping, Vision Research, 2017)
Mechanism of Action
Source: Institute for Basic Science, Center for Vascular Research
- EG-Mirotin (API: EGT022) recruits pericytes to damaged blood vessels deficient of pericytes
- Pericyte recruitment decreases vascular leakage reducing fluid accumulation in the macula, and thereby induces the normalization and stabilization of damaged blood vessels caused by ischemia
EG-Mirotin Highlights
In-vivo Proof-of-Concept
-
OIR mice model
conducted in-house
-
STZ - induced diabetic rat model
conducted at Comparative BioScience, US
Clinical Trial Status
-
Preclinical efficacy
test complete
2012
-
Safety pharmacology
tests complete
2012
-
EMA Phase 1
approval (EU)
2012
-
Phase 1
Complete (EU)2014
-
EMA Phase 2a
approval (EU)
2014
-
EMA Phase 2a
Completed (EU)2020.02
-
MFDS Phase 2
approval (KOR)
2020.03
-
MFDS Phase 2
Completed (KOR)2021.07
- T. +82-2-322-1687
- F. +82-2-302-4359 / +82-2-324-8059
- 본사 : [07528] 서울특별시 강서구 양천로 401 강서한강자이타워 B동 1211호
- 연구소 : [10551] 경기도 고양시 덕양구 의장로 122-1 2층
COPYRIGHTⓒ 2019 EYEGENE lnc. LTD. All RIGHTS RESERVED.
